Turkiye Klinikleri Journal of Ophthalmology

.: ORIGINAL RESEARCH
Tedavi Uygulanan veya Spontan Regrese Olan Prematüre Retinopatili Hastalarda Refraktif Sonuçlar
Refractive Outcomes in Infants with Treated or Spontaneously Regressed Retinopathy of Prematurity
Özge Pınar AKARSU AÇARa, Aslı VURALa, Dilbade YILDIZ EKİNCİb, Gökhan ÇELİKc, Bengi DEMİRAYAKa, Nilay BAKIRa
aİstanbul Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, TÜRKİYE
bKanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, TÜRKİYE
cZeynep Kamil Kadın ve Çocuk Hastalıkları Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, TÜRKİYE
Turkiye Klinikleri J Ophthalmol. 2020;29(1):19-24
doi: 10.5336/ophthal.2019-64716
Article Language: TR
Full Text
ÖZET
 Amaç: Prematüre retinopatisi (PR) nedeni ile intravitreal bevacizumab (IVB) enjeksiyonu veya lazer fotokoagülasyon (LFK) veya IVB ile birlikte geç dönem LFK uygulanan ya da spontan regrese olduğu görülen olguların refraktif sonuçlarının değerlendirilmesidir. Gereç ve Yöntemler: Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi Göz Kliniği PR Tanı ve Tedavi Birimi ve Zeynep Kamil Kadın ve Çocuk Hastalıkları Eğitim ve Araştırma Hastanesi Göz Kliniği PR Tanı ve Tedavi Biriminde tedavi uygulandıktan sonra Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi Göz Kliniği PR Tanı ve Tedavi Biriminde takip edilen hastaların dosyaları retrospektif olarak incelendi. Çalışma kapsamına alınan 133 hasta 4 gruba ayrılarak değerlendirildi. 1. gruba IVB enjeksiyonu yapılan 60 hasta, 2. gruba IVB ile birlikte geç dönem LFK uygulanan 22 hasta, 3. gruba LFK uygulanan 20 hasta ve 4. gruba spontan regrese olduğu görülen 31 hasta dâhil edildi. Refraksiyon değerlendirmesi, çocuklar 18 aylıkken el otorefraktometresiyle yapıldı. Bulgular: LFK grubunda ve IVB ile birlikte geç dönem LFK uygulanan grupta doğum haftası ve doğum kilosu, IVB grubu ve spontan regresyon grubundan anlamlı olarak daha düşük saptandı. IVB ile birlikte geç dönem LFK uygulanan grupta ve IVB grubunda sferik ekivalan spontan regresyon grubundan anlamlı olarak daha düşük bulundu (sırasıyla p=0,002 ve p=0,012). Sonuç: En yüksek miyopi oranı IVB sonrası takip sürecinde geç dönem reaktivasyon saptanarak LFK uygulanan hastalarda görülürken; emetropiye en yakın refraktif değerleri ise spontan regrese olan grupta saptadık ve hastalık aktivitesinin ağırlığı ile refraktif kusurun ilişkili olabileceği sonucuna vardık.

Anahtar Kelimeler: Prematüre retinopatisi; bevacizumab; lazer koagülasyon; miyopi
ABSTRACT
 Objective: To evaluate the refractive outcomes of patients with premature retinopathy (PR) treated with intravitreal bevacizumab (IVB) or laser photocoagulation (LFK) or late-term LFK after IVB or that was spontaneously regressed. Material and Methods: Clinic record archives of infants followed up in Bakırköy Dr. Sadi Konuk Training and Research Hospital, Ophthalmology, PR Diagnose and Treatment Department after getting treatment in Kanuni Sultan Süleyman Training and Research Hospital, Ophthalmology, PR Diagnose and Treatment Department and Zeynep Kamil Maternity and Children's Diseases Training and Research Hospital, Ophthalmology, PR Diagnose and Treatment Department were retrospectively evaluated. 133 patients were examined in 4 groups. 1st group included 60 patients who underwent IVB injection, 2nd group included 22 patients who underwent late-term LFK after IVB, 3rd group included 20 patients who underwent LFK and 4th group included 31 infants with spontaneously regressed PR. The refraction assessment was performed at the age of 18 months with a hand autorefractometer. Results: Gestational age and birth weight were significantly lower in infants who underwent LFK or late-term LFK after IVB than the infants with spontaneously regressed PR. Spherical equivalent was significantly lower in the late-term LFK after IVB and IVB monotherapy groups than the infants with spontaneously regressed PR (p=0.002 and p=0.012, respectively). Conclusion: We found the highest incidence of myopia in the late-term LFK after IVB group and the nearest refractive results to emetropia in infants with spontaneously regressed PR. As a result we concluded that the refractive outcomes are correlated with the severity of PR.

Keywords: Retinopathy of prematurity; bevacizumab; laser coagulation; myopia
REFERENCES:
  1. Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, et al; Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics. 2005;116(1):15-23. [Crossref]  [PubMed] 
  2. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684-94. [Crossref]  [PubMed] 
  3. Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology. 2016;123(9): 1845-55. [Crossref]  [PubMed]  [PMC] 
  4. Axer-Siegel R, Maharshak I, Snir M, Friling R, Ehrlich R, Sherf I, et al. Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes. Retina. 2008;28(6):839-46. [Crossref]  [PubMed] 
  5. Yang CS, Wang AG, Sung CS, Hsu WM, Lee FL, Lee SM. Long-term visual outcomes of laser-treated threshold retinopathy of prematurity: a study of refractive status at 7 years. Eye (Lond). 2010;24(1):14-20. [Crossref]  [PubMed] 
  6. Dhawan A, Dogra M, Vinekar A, Gupta A, Dutta S. Structural sequelae and refractive outcome after successful laser treatment for threshold retinopathy of prematurity. J Pediatr Ophthalmol Strabismus. 2008;45(6):356-61. [Crossref]  [PubMed] 
  7. Sahni J, Subhedar NV, Clark D. Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months. Br J Ophthalmol. 2005;89(2):154-9. [Crossref]  [PubMed]  [PMC] 
  8. Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122(5): 1008-15. [Crossref]  [PubMed]  [PMC] 
  9. Fierson WM; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013;131(1):189-95. [Crossref]  [PubMed] 
  10. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEATROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603-15. [Crossref]  [PubMed]  [PMC] 
  11. Mintz-Hittner HA, Geloneck MM. Review of effects of anti-VEGF treatment on refractive error. Eye Brain. 2016;8:135-40. [Crossref]  [PubMed]  [PMC] 
  12. Özcan E, Yenice Ö, Kazokoğlu H, Bavbek T, Toker E, Özek E. [The incidence and risk factors that play role in development of retinopathy of prematurity in premature babies]. Ret-Vit. 2016;14:127-32.
  13. Koçak N, Arıtürk N. [Risk factors and screening results in retinopathy of prematurity]. Ret-Vit. 2016;24:138-42.
  14. Gül F, Bülbül A. [Evaluation of risk factors affecting development of retinopathy in premature infants]. JAREM. 2018; 8(3):171-6. [Crossref] 
  15. Bas AY, Demirel N, Koc E, Ulubas Isik D, Hirfanoglu İM, Tunc T; TR-ROP Study Group. Incidence, risk factors and severity of retinopathy or prematurity in Turkey (TR-ROP study): a prospective, multicentre study in 69 neonatal intensive care units. Br J Ophthalmol. 2018;102(12):1711-6. [Crossref]  [PubMed]  [PMC] 
  16. Quinn GE, Dobson V, Kivlin J, Kaufman LM, Repka MX, Reynolds JD, et al. Prevalence of myopia between 3 months and 5 1/2 years in preterm infants with and without retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1998;105(7):1292-300. [Crossref] 
  17. Chen YH, Chen SN, Lien RI, Shih CP, Chao AN, Chen KJ, et al. Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye (Lond). 2014:28(9):1080-7. [Crossref]  [PubMed]  [PMC] 
  18. Algawi K, Goggin M, O'Keefe M. Refractive outcome following diode laser versus cryotherapy for eyes with retinopathy of prematurity. Br J Ophthalmol. 1994;78(8):612-4. [Crossref]  [PubMed]  [PMC] 
  19. Gunay M, Sukgen EA, Celik G, Kocluk Y. Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2017;42(3):462-9. [Crossref]  [PubMed] 
  20. Lolas M, Tuma A, Zanolli M, Agurto R, Stevenson R, Ossandón D. Anatomical and refractive outcomes in patients with treated retinopathy of prematurity. Arch Soc Esp Ophthalmol. 2017;92(10):472-6. [Crossref]  [PubMed] 
  21. Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al; BEAT-ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132(11):1327-33. [Crossref]  [PubMed] 
  22. Chuluunbat T, Chan RV, Wang NK, Lien R, Chen YP, Chao AN, et al. Nonresponse and recurrence of retinopathy of prematurity after intravitreal ranibizumab treatment. Ophthalmic Surg Lasers Imaging Retina. 2016;47(12):1095-105. [Crossref]  [PubMed] 
  23. Gunay M, Celik G, Gunay BO, Aktas A, Karatekin G, Ovali F. Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol. 2015;78(5):300-4. [Crossref]  [PubMed] 
  24. Kabataş EU, Kurtul BE, Altıaylık Özer P, Kabataş N. Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children. Curr Eye Res. 2017;42(7):1054-8. [Crossref]  [PubMed] 
  25. Gunay M, Sekeroglu MA, Bardak H, Celik G, Esenulku CM, Hekimoglu E, et al. Evaluation of refractive errors and ocular biometric outcomes after intravitreal bevacizumab for retinopathy of prematurity. Strabismus. 2016;24(2):84-8. [Crossref]  [PubMed] 
  26. Kuo HS, Sun TI, Chung MY, Chen YH. Refractive error in patients with retinopathy of prematurity after laser photocoagulation or bevacizumab monotheraphy. Ophthalmologica. 2015;234(4):211-7. [Crossref]  [PubMed] 
  27. Adams G, Bunce C, Xing W, Butler L, Long V, Reddy A, et al; UK Retinopathy of Prematurity Special Interest Group. Retinopathy of prematurity in the United Kingdom: retreatment rates,visual and structural 1-year outcomes. Eye (Lond). 2018;32(11):1752-9. [Crossref]  [PubMed]  [PMC] 
  28. Li Z, Zhang Y, Liao Y, Zeng R, Zeng P, Lan Y. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in type-1 and threshold retinopathy of prematurity (ROP). BMC Ophthalmol. 2018;18(1):19. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com